(function(){ var content_array=["

鍏充簬<\/b>EMPEROR<\/b>蹇冨姏琛扮鐮旂┒<\/b>[15],[16] <\/p> \n

EMPEROR锛堥噰鐢ㄦ仼鏍煎垪鍑€娌荤枟鎱㈡€у績琛版偅鑰呯殑缁撳眬璇曢獙锛夋參鎬у績琛扮爺绌跺寘鎷袱椤笽II鏈熴€侀殢鏈恒€佸弻鐩茶瘯楠岋紝閽堝灏勮鍒嗘暟闄嶄綆涓庡皠琛€鍒嗘暟淇濈暀鐨勬垚浜烘參鎬у績琛版偅鑰咃紙鍧囧寘鎷即涓庝笉浼寸硸灏跨梾鐨勬偅鑰咃級锛屽湪鎺ュ彈鏍囧噯娌荤枟鐨勫熀纭€涓婏紝鐮旂┒姣忔棩涓€娆℃仼鏍煎垪鍑€涓庡畨鎱板墏鐩告瘮鐨勭枟鏁堜笌瀹夊叏鎬э細<\/p> \n

\n
EMPEROR-Reduced [NCT03057977<\/a><\/u>]锛氳瘎浼版仼鏍煎垪鍑€娌荤枟灏勮鍒嗘暟闄嶄綆鐨勬參鎬у績鍔涜“绔紙HFrEF锛夋偅鑰呯殑瀹夊叏鎬т笌鐤楁晥 <\/li> \n
\n
涓昏缁堢偣锛氳嚦棣栨琚 瀹氫负蹇冭绠℃浜′簨浠舵垨琚 瀹氫负鍥犲績琛拌€屼綇闄㈢殑鏃堕棿 <\/li> \n
鍏ョ粍鎮ｈ€呬汉鏁帮細3,730渚� <\/li> \n
瀹屾垚鏃堕棿锛�2020骞�<\/li> \n <\/ul> \n
EMPEROR-Preserved [NCT03057951<\/a>]锛氳瘎浼版仼鏍煎垪鍑€娌荤枟灏勮鍒嗘暟淇濈暀鐨勬參鎬у績鍔涜“绔紙HFpEF锛夋偅鑰呯殑瀹夊叏鎬т笌鐤楁晥銆� <\/li> \n
\n
涓昏缁堢偣锛氳嚦棣栨琚 瀹氫负蹇冭绠℃浜′簨浠舵垨琚 瀹氫负鍥犲績琛拌€屼綇闄㈢殑鏃� <\/li> \n
鍏ョ粍鎮ｈ€呬汉鏁帮細5,988渚� <\/li> \n
瀹屾垚鏃堕棿锛�2021骞� <\/li> \n
瀹屾垚鏃堕棿锛�2021骞�<\/li> \n <\/ul> \n<\/ul> \n
鍏充簬<\/b>EMPOWER<\/b>椤圭洰<\/b><\/p> \n
鑱旂洘寮€鍙戜簡EMPOWER椤圭洰锛屾棬鍦ㄦ帰绱㈡仼鏍煎垪鍑€瀵逛竴绯诲垪蹇冭剰-鑲捐剰-浠ｈ阿鐤剧梾鐨勪富瑕佷复搴婂績琛€绠″拰鑲捐剰缁撳眬鐨勫奖鍝嶃€傚績鑲句唬璋㈢柧鐥呮槸鍏ㄧ悆姝讳骸鐨勪富瑕佸師鍥狅紝姣忓勾瀵艰嚧鐨勬浜＄梾渚嬮珮杈�2000涓囥€俒17]閫氳繃EMPOWER椤圭洰锛屽媰鏋楁牸娈锋牸缈板拰绀兼潵姝ｅ湪鍔姏澧炲姞瀵硅繖浜涚浉鍏崇郴缁熺殑璁ょ煡锛屽苟寮€鍙戝彲鎻愪緵缁煎悎銆佸鍣ㄥ畼鑾风泭鐨勬不鐤椼€侲MPOWER鐢�9椤逛复搴婅瘯楠屽拰涓ら」鐪熷疄涓栫晫鐮旂┒缁勬垚锛孍MPEROR寮哄寲浜嗚仈鐩熷鏀瑰杽蹇冭剰-鑲捐剰-浠ｈ阿鐤剧梾鎮ｈ€呬复搴婃不鐤楃粨灞€鐨勯暱鏈熸壙璇恒€備复搴婄爺绌跺叏鐞冨叆缁勮秴杩�400锛�000浣嶆垚浜烘偅鑰咃紝EMPOWER鏄縿浠婁负姝㈤拡瀵筍GLT2鎶戝埗鍓傚紑灞曠殑鏈€骞挎硾鍜屾渶鍏ㄩ潰鐨勪复搴婇」鐩箣涓€銆�<\/p> \n
鍏充簬蹇冨姏琛扮<\/b><\/p> \n
蹇冨姏琛扮鏄竴绉嶈繘琛屾€у姞閲嶃€佸鑷磋櫄寮卞苟鍙兘鍗卞強鐢熷懡鐨勭柧鐥咃紝褰撳績鑴忎笉鑳戒緵搴旇冻澶熺殑琛€娑插惊鐜互婊¤冻韬綋瀵瑰惈姘ц娑茬殑闇€姹傛垨闇€瑕佸鍔犺瀹归噺瀵艰嚧鑲洪儴鍜屽鍛ㄧ粍缁囨恫浣撶Н鑱氾紙鍏呰锛夋椂鍙戠敓銆俒18]^{,<\/sup>[19]蹇冨姏琛扮鏄竴绉嶅父瑙佺殑鐤剧梾锛岀疮鍙婂叏鐞�6000涓囦汉锛孾3,4] 鍏跺彂鐥呯巼棰勮浼氶殢鐫€浜哄彛鑰侀緞鍖栬€屽鍔犮€傚績鍔涜“绔湪绯栧翱鐥呮偅鑰呬腑闈炲父鏅亶锛孾20] 鐒惰€屽ぇ绾︿竴鍗婄殑蹇冨姏琛扮鎮ｈ€呬笉浼存湁绯栧翱鐥呫€俒21]<\/p> \n}
蹇冨姏琛扮鏈変笉鍚岀殑绫诲瀷銆傛偅鑰呭彲浠ヤ即鏈夊乏渚у皠琛€鍒嗘暟闄嶄綆鎴栦繚鐣欑殑蹇冨姏琛扮銆傚皠琛€鍒嗘暟鏄祴閲忔瘡娆″乏蹇冨鏀剁缉鏃舵车鍑虹殑琛€娑茬櫨鍒嗘瘮銆俒22]褰撳績鑴忚垝寮犳椂锛屽績瀹ら噸鏂板厖婊¤娑层€�<\/p> \n
\n
褰撳績鑴忕殑宸﹀績瀹ゆ棤娉曡垝寮犲苟姝ｅ父鍏呯泩鏃跺彂鐢熷皠琛€鍒嗘暟淇濈暀鐨勫績鍔涜“绔紝瀵艰嚧鍙緵娉靛嚭鍒拌韩浣撶殑琛€娑插噺灏戙€俒22] <\/li> \n
褰撳績鑴忕殑宸﹀績瀹や笉鑳芥湁鏁堟敹缂╂椂鍙戠敓灏勮鍒嗘暟闄嶄綆鐨勫績鍔涜“绔紝杩欐剰鍛崇潃蹇冭剰涓嶈兘鐢ㄨ冻澶熺殑鍔涢噺娉佃锛屽洜姝ゆ帓鍑哄埌韬綋鐨勮娑插噺灏戙€傘€俒22]<\/li> \n<\/ul> \n
蹇冨姏琛扮鎮ｈ€呯粡甯镐細鍑虹幇鍛煎惛鍥伴毦鍜岀柌鍔筹紝杩欎細涓ラ噸褰卞搷浠栦滑鐨勭敓娲昏川閲忋€俒23]鎮ｆ湁蹇冨姏琛扮鐨勬偅鑰呴€氬父涔熸湁鑲惧姛鑳藉彈鎹燂紝杩欎細瀵归鍚庝骇鐢熸樉钁楃殑璐熼潰褰卞搷銆俒24]<\/p> \n
鍏充簬蹇冭剰<\/b>-<\/b>鑲捐剰<\/b>-<\/b>浠ｈ阿鐤剧梾<\/b>
<\/p> \n
鍕冩灄鏍兼鏍肩堪鍜岀ぜ鏉ュ笇鏈涜兘鏀瑰彉蹇冭剰-鑲捐剰-浠ｈ阿鐤剧梾鎮ｈ€呯殑娌荤枟鏂瑰紡锛岃繖鏄竴缁勭浉浜掑叧鑱旂殑鐤剧梾锛屽奖鍝嶅叏鐞冭秴杩�10浜夸汉锛屾槸姝讳骸鐨勪富瑕佸師鍥犮€俒4,17]<\/p> \n
蹇冭绠°€佽偩鑴忓拰浠ｈ阿绯荤粺鐩镐簰鍏宠仈锛屽湪鐤剧梾璋变腑鍏锋湁璁稿鐩稿悓鐨勯闄╁洜绱犲拰鐥呯悊閫斿緞銆備竴涓郴缁熺殑鍔熻兘闅滅鍙兘浼氬姞閫熷叾瀹冪郴缁熺殑鍙戠梾锛屼粠鑰屽鑷寸浉鍏崇柧鐥呯殑鍙戝睍锛屽2鍨嬬硸灏跨梾銆佸績琛€绠＄柧鐥呫€佸績鍔涜“绔拰鑲捐剰鐤剧梾绛夌浉浜掑叧鑱旂殑鐤剧梾锛岃繘鑰屽鑷村績琛€绠℃浜￠闄╁鍔犮€傜浉鍙嶏紝涓€涓郴缁熺殑鏀瑰杽鍙互鍦ㄥ叾瀹冪郴缁熶腑浜х敓绉瀬鐨勫奖鍝嶃€俒25],[26],[27]<\/p> \n
閫氳繃鎴戜滑鐨勭爺绌跺拰娌荤枟锛屾垜浠殑鐩爣鏄敮鎸佹偅鑰呯殑鍋ュ悍锛屾仮澶嶇浉浜掑叧鑱旂殑蹇冭剰-鑲捐剰-浠ｈ阿绯荤粺涔嬮棿鐨勫钩琛★紝骞堕檷浣庝粬浠彂鐢熶弗閲嶅苟鍙戠棁鐨勯闄┿€備綔涓哄閭ｄ簺鍋ュ悍鍙楀埌蹇冭剰-鑲捐剰-浠ｈ阿鐤剧梾鍗卞鎮ｈ€呮壙璇虹殑涓€閮ㄥ垎锛屾垜浠皢缁х画鐮旂┒澶氬绉戞不鐤楁柟妗堬紝骞跺皢鎴戜滑鐨勮祫婧愰泦涓湪濉 ˉ娌荤枟绌虹櫧涓娿€�<\/p> \n
鍏充簬鎭╂牸鍒楀噣<\/b><\/p> \n
鎭╂牸鍒楀噣锛堝晢鍝佸悕涓烘鍞愰潤® 锛夋槸涓€绉嶅彛鏈嶃€佹瘡鏃ヤ竴娆°€侀珮閫夋嫨鎬ч挔-钁¤悇绯栧崗鍚岃浆杩愯泲鐧�2锛圫GLT2锛夋姂鍒跺墏锛屼篃鏄涓湪璇稿鍥藉鐨勮鏄庝功涓寘鍚檷浣庡績琛€绠℃浜￠闄╂暟鎹殑2鍨嬬硸灏跨梾鑽墿銆俒9,10,11]<\/p> \n
鍏充簬鍕冩灄鏍兼鏍肩堪鍜岀ぜ鏉�<\/b><\/p> \n
2011骞�1鏈堬紝鍕冩灄鏍兼鏍肩堪鍏徃鍜岀ぜ鏉ュ埗鑽甯冭揪鎴愬悎浣滃崗璁紝鍚堜綔鍐呭鍖呮嫭鏁扮被闄嶇硸鑽墿鐨勫涓搧绉嶃€傚熀浜庝笉鍚岀殑甯傚満锛屽弻鏂瑰皢閫夋嫨鍏卞悓鎺ㄥ箍鎴栧崟鐙帹骞垮悇鑷负姝ら」鍚堜綔鎵€鎻愪緵鐨勮嵂鐗┿€傝繖椤瑰悎浣滄暣鍚堜簡涓ゅぇ涓撴敞浜庢偅鑰呴渶姹傜殑鍏ㄧ悆棰嗗厛鍒惰嵂鍏徃鐨勫疄鍔涳紝閫氳繃鎼烘墜鍚堜綔锛屼袱瀹跺叕鍙告壙璇鸿嚧鍔涗簬甯姪绯栧翱鐥呮偅鑰咃紝骞舵帰绱㈣В鍐虫偅鑰呮湭婊¤冻鐨勫尰鐤楅渶姹傘€傝瘎浼版仼鏍煎垪鍑€瀵瑰績鍔涜“绔垨鎱㈡€ц偩鑴忕柧鐥呮偅鑰呭奖鍝嶇殑涓村簥璇曢獙宸茬粡鍚姩銆�<\/p> \n
鍏充簬鍕冩灄鏍兼鏍肩堪<\/b><\/p> \n
鍕冩灄鏍兼鏍肩堪鑷村姏浜庣爺绌剁獊鐮存€х枟娉曪紝鏃ㄥ湪鏀瑰杽浜虹被鍜屽姩鐗╃殑鍋ュ悍銆備綔涓轰竴瀹剁爺鍙戦┍鍔ㄧ殑鍏ㄧ悆棰嗗厛鐢熺墿鍒惰嵂浼佷笟锛屽叕鍙稿湪鍖荤枟闇€姹傞珮搴︽湭寰楀埌婊¤冻鐨勯鍩熼€氳繃鍒涙柊灞曠幇浠峰€笺€傝嚜1885骞存垚绔嬩互鏉ワ紝鍕冩灄鏍兼鏍肩堪濮嬬粓鏄竴瀹剁嫭绔嬬殑瀹舵棌浼佷笟锛屼粠闀胯繙鏉ョ湅杩欎竴鐐瑰皢涓嶄細鏀瑰彉銆傚湪浜虹敤鑽搧銆佸姩鐗╀繚鍋ュ拰鐢熺墿鍒惰嵂鍚堝悓鐢熶骇涓夊ぇ涓氬姟棰嗗煙锛屽叏鐞冩湁绾�5.2涓囧悕鍛樺伐鏈嶅姟閫�130涓湴鍖恒€傛洿澶氳鎯咃紝璇疯闂細www.boehringer-ingelheim.com<\/a><\/p> \n
鍏充簬绀兼潵鍏徃<\/b>

<\/p> \n
浣滀负鍏ㄧ悆鍖荤枟鍋ュ悍浜т笟棰嗗鑰咃紝绀兼潵鑷村姏浜庝互鍒涙柊鍥炴姤鎮ｈ€呫€佷互鍏崇埍鍛垫姢鐢熷懡銆傚垱绔嬩竴鐧惧洓鍗佷綑骞存潵锛岀ぜ鏉ュ缁堝琛岀潃浠ユ渶鏂版妧鏈负鎮ｈ€呮彁渚涙渶浼樿川鑽搧鐨勭悊蹇碉紝杩欎笌鍏徃鍒涘浜虹ぜ鏉ヤ笂鏍＄殑鎵胯涓€鑴夌浉鎵裤€備粖澶╋紝绀兼潵浠嶇劧鎵х潃浜庤繖涓€浣垮懡锛屽苟鎹寮€灞曞悇椤瑰伐浣溿€備笘鐣屽悇鍥界殑绀兼潵浜轰笉浠呮綔蹇冪爺鍙戞尳鏁戠敓鍛界殑鑽搧銆佺Н鏋佸府鍔╂偅鑰呮洿濂藉湴璁よ瘑鍜岀鐞嗙柧鐥咃紝杩橀€氳繃鎱堝杽鍏泭娲诲姩鍏ㄥ績鍥為绀句細銆傛浜嗚В鏇村鍏充簬绀兼潵鍒惰嵂鐨勪俊鎭紝璇风櫥褰� http:\/\/www.lilly.com<\/a> 鍜�https:\/\/newsroom.lilly.com\/social-channels<\/a>.<\/p> \n
CONTACTS:<\/b><\/p> \n
Stefanie Molkenthin<\/span><\/b>
Product Communication Manager
Boehringer Ingelheim
Email: press@boehringer-ingelheim.com<\/a>
Phone: +49 (6132) 77 172 209<\/p> \n
Anna Bergmann<\/span>
<\/b>Global Business Communications
Eli Lilly and Company
Email: anna.bergmann@lilly.com<\/a>
Phone: +1 317 864 3143<\/p> \n
References<\/b><\/p> \n
[1] Anker S, Butler J, Filippatos G, et al<\/i>. Empagliflozin in Heart Failure With a Preserved Ejection Fraction. N Engl J Med<\/i>. 2021;[insert]. <\/p> \n
[2] Anker S. EMPEROR-Preserved: effect of empagliflozin on cardiovascular death and heart failure hospitalisations in patients with heart failure with a preserved ejection fraction, with and without diabetes. Presented on 27 August 2021<\/span> at the European Society of Cardiology (ESC) Congress 2021 鈥� The Digital Experience.<\/p> \n
[3] Andersen MJ, Borlaug BA. Heart failure with preserved ejection fraction: current understandings and challenges. Curr Cardiol Rep<\/i>. 2014;16(7):501.<\/p> \n
[4] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990鈥�2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet.<\/i> 2018;392(10159):1789鈥�858.<\/p> \n
[5] Butler J, Fonarow G, Zile M, et al<\/i>. Developing therapies for heart failure with preserved ejection fraction: Current State and Future Directions. JACC Heart Fail<\/i>. 2014 Apr;2(2):97鈥�112.<\/p> \n
[6] Shah SJ, Borlaug B, Kitzman D, et al<\/i>. Research priorities for heart failure with preserved ejection fraction. Circulation<\/i>. 2020;141:1001鈥�26.<\/p> \n
[7] Boehringer Ingelheim. Data on file.<\/p> \n
[8] Packer M, Anker SD, Butler J, et al<\/i>. Cardiac and Renal Outcomes With Empagliflozin in Heart Failure With a Reduced Ejection Fraction. N Engl J Med.<\/i> 2020;383:1413鈥�24.<\/p> \n
[9] Jardiance® (empagliflozin) tablets. European Product Information, approved April 2020<\/span>. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jardiance-epar-product-information_en.pdf<\/a>. Accessed August 2021<\/span>.<\/p> \n
[10] Jardiance^{®<\/sup> (empagliflozin) tablets, U.S. Prescribing Information. Available at:}http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Jardiance\/jardiance.pdf<\/a>. Accessed: August 2021<\/span>.<\/p> \n
[11] Jardiance^{®<\/sup> (Full Prescribing Information). Mexico<\/span>; Boehringer Ingelheim Pharmaceuticals, Inc; 2017.<\/p> \n}
[12] [PDUFA announcement].<\/p> \n
[13] ClinicalTrials.gov. EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509674<\/a>. Accessed: August 2021<\/span>.<\/p> \n
[14] ClinicalTrials.gov. EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin). Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03594110<\/a>. Accessed: August 2021<\/span>.<\/p> \n
[15] ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057977<\/a>. Accessed: August 2021<\/span>.<\/p> \n
[16] ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057951<\/a>. Accessed: August 2021<\/span>.<\/p> \n
[17] GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980鈥�2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet<\/i>. 2016; 388(10053):1459鈥�544.<\/p> \n
[18] American Heart Association. What is Heart Failure? Available at: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure<\/a>. Accessed: August 2021<\/span>.<\/p> \n
[19] American Heart Association. Types of Heart Failure. Available at: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/types-of-heart-failure<\/a>. Accessed: August 2021<\/span>.<\/p> \n
[20] Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. <\/i>2019;124(1):121鈥�41.<\/p> \n
[21] Dunlay SM, Givertz MM, Aguilar D, et al.<\/i> Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America. Circulation.<\/i> 2019;140:e294鈥揺324.<\/p> \n
[22] American Heart Association. Ejection Fraction Heart Failure Measurement. Available at: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/diagnosing-heart-failure\/ejection-fraction-heart-failure-measurement<\/a>. Accessed: August 2021<\/span>.<\/p> \n
[23] Calvert MJ, Freemantle N, Cleland JGF. The impact of chronic heart failure on health鈥搑elated quality of life data acquired in the baseline phase of the CARE鈥揌F study. Eur J Heart Fail<\/i>. 2005;7(2):243鈥�51.<\/p> \n
[24] Sarnak MJ. A patient with heart failure and worsening kidney function. Clin J Am Soc Nephrol<\/i>. 2014;9(10):1790鈥�98.<\/p> \n
[25] García-Donaire JA, Ruilope LM. Cardiovascular and Renal Links along the Cardiorenal Continuum. Int J Nephrol<\/i>. 2011;2011:975782.<\/p> \n
[26] Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes<\/i>. 2015;6(13):1246鈥�58.<\/p> \n
[27]^{<\/sup>Thomas M, Cooper M, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. <\/i>2015;12:73鈥�81.<\/p>"];
$("#dvExtra").html(content_array[0]);})();}